Find
News Releases
| All | ||||||
|---|---|---|---|---|---|---|
 |
Cordis Unveils Next Generation CoCr Coronary Stent Mar 11, 2010 |
6.8 KB |
|
|||
|
Bridgewater, New Jersey - March 10, 2010 - Cordis Corporation today announced the European launch of its next generation of bare metal stent system - PRESILLION ™ PLUS. The new stent system, which improves upon the ground-breaking PRESILLION™, features important technological advances designed to gain easier access to distal le... |
||||||
|
Johnson & Johnson Consumer Companies, Inc., Unveils CYTOMIMIC(TM) Technology at 68th Annual Meeting of the American Academy of Dermatology Mar 5, 2010 |
10.5 KB |
|
|||
|
MIAMI BEACH, Fla., March 5, 2010 /PRNewswire via COMTEX News Network/ -- Building on decades of research into how the body's electrical field affects skin regeneration, scientists at Johnson & Johnson Consumer Companies, Inc., have discovered how to harness the power of bioelectricity to help improve skin rejuvenation. The new innovation, called C... |
||||||
|
STELARATM and REMICADE® Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting Mar 4, 2010 |
19.3 KB |
|
|||
|
Miami, March 4, 2010 -Data evaluating the efficacy and safety of STELARA™(ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, F... |
||||||
|
Johnson & Johnson to Participate in the 30th Annual Cowen and Company Health Care Conference Mar 2, 2010 |
5.5 KB |
|
|||
|
NEW BRUNSWICK, N.J., March 2, 2010 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 30th Annual Cowen and Company Health Care Conference on Tuesday, March 9th at the Boston Marriott Copley Place Hotel in Boston, MA. Seth Fischer, Company Group Chairman, Worldwide Franchise Chairman, Cordis, will represe... |
||||||
|
New Guidelines Recommend DORIBAX® For Initial Treatment Of Complicated Intra-Abdominal Infections In Adults Feb 24, 2010 |
56.9 KB |
|
|||
|
Raritan, NJ - February 24, 2010 - Ortho-McNeil, Inc. announced today its antibiotic DORIBAX® (doripenem for injection) has received an A-1 recommendation (highest rating) as a single agent in the initial treatment of certain high-risk complicated intra-abdominal infections (cIAI), according to newly-updated diagnosis and management guidel... |
||||||
|
LifeScan Recalls Specific Lots of Consumer and Professional OneTouch® SureStep® Test Strips Due To Inaccurate Readings at High Levels Feb 24, 2010 |
54.0 KB |
|
|||
|
MILPITAS, Calif., Feb. 24 LifeScan, Inc. is conducting a voluntary recall in the United States of eight lots of OneTouch® SureStep® Test Strips, used by people with diabetes to measure their blood glucose levels at home. The test strips are being recalled because they may provide falsely low glucose results when the glucose level is higher t... |
||||||
|
Johnson & Johnson to Participate in RBC Capital Markets' Health Care Conference Feb 23, 2010 |
5.5 KB |
|
|||
|
NEW BRUNSWICK, N.J., Feb 23, 2010 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson will participate in the RBC Capital Markets' Health Care Conference on Tuesday, March 2, 2010, at the New York Palace Hotel, New York, NY. Dominic Caruso, Vice President, Finance and Chief Financial Officer, will participate in a session scheduled at 11:00... |
||||||
|
Ethicon Endo-Surgery Announces Agreement with Hologic Inc. To Resolve Patent Disputes Feb 19, 2010 |
6.9 KB |
|
|||
|
Cincinnati, OH (February 19, 2010) – Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon End... |
||||||
|
CHMP adopts negative opinion for ZEFTERA™ Feb 19, 2010 |
7.1 KB |
|
|||
|
Beerse, Belgium, 19th February 2010 - Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on its Marketing Authorisation Application (MAA) for the antibiotic ZEFTERA™ (ceftobiprole medocaril), for the ... |
||||||
|
New Study Compares Efficacy And Safety Of Once-Daily Versus Twice-Daily Prezista® Regimen In Treatment-Experienced Adult Patients With No Prezista Mutations Feb 17, 2010 |
66.5 KB |
|
|||
|
[San Francisco, Feb. 17, 2010] - In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir ® (800/100 mg) once-daily arm achieved undetectable viral loads (... |
||||||
|
Centocor Ortho Biotech Products and Amgen Finalize ESA Risk Evaluation and Mitigation Strategy (Rems) with FDA Feb 16, 2010 |
13.5 KB |
|
|||
|
Horsham, Pa., February 16, 2010 - Centocor Ortho Biotech Products, L.P. and Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include PROCRIT® (Epoetin alfa), Aranesp® (darbepoetin alfa) and EPOGEN®... |
||||||
|
PREZISTA®* Now Approved as Part of Combination Therapy for Pediatric Patients Six Years of Age and Older with HIV Feb 9, 2010 |
10.9 KB |
|
|||
|
Toronto, ON (February 9, 2010) - Tibotec, a division of Janssen-Ortho Inc., announced that Health Canada has approved PREZISTA® (darunavir) for use in children with HIV between the ages of six and 18, dosed twice daily in combination with ritonavir and other antiretroviral agents. PREZISTA® is a protease inhibitor that works by bl... |
||||||
|
Tapentadol Extended Release Data To Be Presented At American Academy Of Pain Medicine Annual Meeting Feb 4, 2010 |
16.6 KB |
|
|||
|
San Antonio, TX - February 4, 2010 - Data from three important studies on tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older, will be discussed during the poster sessions of the 26th Annual Meeting of the American Academy of Pain M... |
||||||
|
Cordis Corporation Announces Agreement With Boston Scientific To Resolve Certain Coronary Stent Patent Disputes Feb 1, 2010 |
7.8 KB |
|
|||
|
BRIDGEWATER, N.J., Feb 01, 2010 /PRNewswire via COMTEX News Network/ -- Cordis Corporation, a Johnson & Johnson company, announced today that it has reached an agreement with Boston Scientific resolving two Delaware litigations related to Cordis's Palmaz and Gray patents and Boston Scientific's Jang patents. Under the terms of the agreement, Cord... |
||||||
|
U.S. Food and Drug Administration Approves Labeling Update for PREZISTA® To Include 96-Week Data in HIV-1 Infected Adult Patients Jan 27, 2010 |
15.3 KB |
|
|||
|
BRIDGEWATER, N.J., Jan. 27 /PRNewswire/ -- Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA® (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies. Both ARTEMIS and TITAN evaluated the efficacy and safety of PREZISTA with ritonavir ... |
||||||
|
Johnson & Johnson Reports 2009 Fourth-Quarter and Full-Year Results: Jan 26, 2010 |
26.5 KB |
|
|||
|
NEW BRUNSWICK, N.J., Jan 26, 2010 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson today announced sales of $16.6 billion for the fourth quarter of 2009, an increase of 9.0% as compared to the fourth quarter of 2008. Operational growth was 4.5% and currency contributed 4.5%. Domestic sales were up 2.6%, while international sales increased... |
||||||
|
Ethicon Completes Acquisition of Acclarent Jan 20, 2010 |
6.1 KB |
|
|||
|
SOMERVILLE, N.J., Jan 20, 2010 /PRNewswire via COMTEX News Network/ -- Ethicon, Inc., announced today that it has completed the acquisition of Acclarent, Inc., following clearance under the Hart-Scott-Rodino Antitrust Improvement Act. Acclarent is a privately held medical technology company dedicated to designing, developing and commercializing d... |
||||||
|
Johnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter and Full-Year 2009 Financial Results Jan 19, 2010 |
6.0 KB |
|
|||
|
NEW BRUNSWICK, N.J., Jan 19, 2010 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, January 26, 2010, to discuss fourth-quarter and full-year 2009 financial results. The meeting will be hosted by William C. Weldon, Chairman and Chief Executive Officer; Dominic J. Caruso,... |
||||||
|
McNeil Consumer Healthcare Announces Voluntary Recall of Certain Over-the-Counter (OTC) Products in the Americas, UAE, and Fiji Jan 15, 2010 |
885.4 KB |
|
|||
|
Fort Washington, PA (January 15, 2010) - In consultation with the U.S. Food and Drug Administration (FDA), McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is voluntarily recalling certain lots of OTC products in the Americas, the United Arab Emirates (UAE), and Fiji (FULL RECALLED PRODUCT LIST BELOW). The company is initiating this rec... |
||||||
|
Stelara®* Shows Greater Efficacy than Etanercept for Treatment of Moderate-to-Severe Plaque Psoriasis Jan 14, 2010 |
18.0 KB |
|
|||
|
Toronto, ON, January 14, 2010 - Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA® (ustekinumab) with Enbrel† (etanercept) in the treatment of moderate to severe plaque psoriasis showed a significantly higher clinical response ... |
||||||
|
||||||
= add release to Briefcase